Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Emergency department (ED) readmission was more common than dermatology outpatient follow-up among patients with hidradenitis suppurativa (HS) who initially presented to the ED, with Medicaid insurance and having an opioid prescription cited as risk factors for ED readmission. Findings were published in JAMA Dermatology.
HS is a debilitating skin disease characterized by painful nodules, abscesses, and sinus tracts that affect patients physically and psychosocially. Researchers note that many barriers to proper medical care for patients with HS exist and that the condition is exacerbated by frequent misdiagnoses.
Further, once a diagnosis is made, patients with HS receive a large proportion of their care outside of the ambulatory dermatology setting, including frequently in high-cost ED and inpatient settings.
“The overreliance on nonambulatory settings in HS care is critical to recognize for several reasons. This pattern results in increased costs to the health care system and the patient,” said the study authors.
“Additionally, lack of consistent dermatology follow-up may result in delays in optimal care for these patients. Interventions such as incision and drainage (I&D), short-term antibiotic prescription, and opioid prescription are common at ED encounters for HS, but these are temporizing remedies that do not contribute toward long-term medical control of the disease.”
Patients with HS have high ED utilization for their disease and relatively low outpatient utilization, but the study researchers said it is still unclear what ED interventions and patient characteristics may be associated with these outcomes.
They conducted a retrospective cohort study using data from the IBM MarketScan Commercial and Multi-State Medicaid databases from 2010 to 2019 to assess the interventions and patient factors associated with ED return following an initial ED visit for HS.
An HS cohort was formed from the databases of patients who had 2 or more claims for HS during the study period, with at least 1 ED visit for their HS or a defined proxy. Data were analyzed from November 2021 to May 2022. Participants were examined for the primary outcomes of a return to the ED or dermatology outpatient follow-up for HS or related proxy within 30 or 180 days of index ED visit.
A total of 20,269 patients with HS (median [IQR] age, 32 [25-41] years; 16,804 [82.9%] female patients) were included in the analysis, of which 7455 (36.8%) had commercial insurance and 12,814 (63.2%) had Medicaid.
Of the study cohort, 9737 (48.0%) patients had I&D performed at the index ED visit; 14,725 (72.6%) received an oral antibiotic prescription; and 9913 (48.9%) received an opioid medication prescription.
Participants were shown to be more likely to report an ED return vs dermatology outpatient follow-up at both 30 and 180 days after their initial ED visit, in which patients with Medicaid and those who had an opioid prescribed were more likely to return to the ED for treatment of their disease and less likely to have dermatology follow-up:
The lack of granularity provided by large administrative databases was cited as a potential limitation of the study findings, as it prevented researchers from identifying certain details regarding patient and treatment information. The restriction of the patient population to those with continuous insurance coverage over a certain period also may have prevented the inclusion of some vulnerable patients, said the researchers.
“The findings in this study raise the opportunity for cross-specialty interventions that could be implemented to better connect patients with HS to longitudinal care,” they concluded.
Reference
Wang CX, Buss JL, Keller M, Anadkat MJ. Factors associated with dermatologic follow-up vs emergency department return in patients with hidradenitis suppurativa after an initial emergency department visit. JAMA Dermatol. Published online October 26, 2022. doi:10.1001/jamadermatol.2022.4610
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More